Uveal Melanoma Clinical Trials

22 recruiting

Uveal Melanoma Trials at a Glance

35 actively recruiting trials for uveal melanoma are listed on ClinicalTrialsFinder across 6 cities in 22 countries. The largest study group is Phase 2 with 14 trials, with the heaviest enrollment activity in Philadelphia, Tampa, and Los Angeles. Lead sponsors running uveal melanoma studies include H. Lee Moffitt Cancer Center and Research Institute, Aura Biosciences, and IDEAYA Biosciences.

Browse uveal melanoma trials by phase

Treatments under study

About Uveal Melanoma Clinical Trials

Looking for clinical trials for Uveal Melanoma? There are currently 22 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Uveal Melanoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Uveal Melanoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 35 trials

Recruiting
Phase 1

Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis

Uveal Melanoma, Metastatic
St Vincent's Hospital, Sydney8 enrolled2 locationsNCT07203391
Recruiting
Phase 2

Neoadjuvant Tebentafusp for Uveal Melanoma

Locally Advanced Unresectable Uveal Melanoma
Thomas Jefferson University19 enrolled2 locationsNCT06414590
Recruiting
Phase 1

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Lung Non-Small Cell CarcinomaMetastatic Melanoma+7 more
M.D. Anderson Cancer Center75 enrolled1 locationNCT03025256
Recruiting
Phase 2

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

Uveal MelanomaOcular Melanoma
H. Lee Moffitt Cancer Center and Research Institute37 enrolled1 locationNCT05524935
Recruiting
Phase 2Phase 3

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Metastatic Uveal Melanoma
Replimune, Inc.280 enrolled33 locationsNCT06581406
Recruiting
Phase 2

Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma

Metastatic Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute18 enrolled1 locationNCT07276386
Recruiting
Not Applicable

Identification of New Candidate Genes for Hereditary Predisposition to Uveal Melanoma

Uveal Melanoma
Centre Jean Perrin50 enrolled1 locationNCT06550674
Recruiting
Phase 1

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Breast CancerHead and Neck Squamous Cell CarcinomaMetastatic Malignant Solid Neoplasm+14 more
Anusha Kalbasi18 enrolled3 locationsNCT04119024
Recruiting
Phase 1

A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma

Melanoma MetastaticMucosal MelanomaUveal Melanoma, Metastatic
Alpha-9 Oncology USA Inc.50 enrolled4 locationsNCT07076550
Recruiting
Not Applicable

Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver

Uveal Melanoma
Massachusetts General Hospital10 enrolled1 locationNCT07364474
Recruiting

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

CholangiocarcinomaHepatocellular CarcinomaRenal Cell Carcinoma+5 more
Mohamed Abdel-Rahman500 enrolled1 locationNCT04792463
Recruiting
Phase 2

Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma

Mestastatic Uveal Melanoma
Grupo Español Multidisciplinar de Melanoma19 enrolled4 locationsNCT07057596
Recruiting
Phase 3

Adjuvant Tebentafusp in High Risk Ocular Melanoma

Uveal Melanoma
European Organisation for Research and Treatment of Cancer - EORTC290 enrolled14 locationsNCT06246149
Recruiting
Phase 1

Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours

Advanced Solid TumorCutaneous MelanomaUveal Melanoma, Metastatic
MonTa Biosciences ApS106 enrolled5 locationsNCT04855435
Recruiting
Phase 3

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

Uveal MelanomaChoroidal MelanomaIndeterminate Lesions+1 more
Aura Biosciences100 enrolled71 locationsNCT06007690
Recruiting
Phase 2

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

Uveal Melanoma
Diwakar Davar44 enrolled3 locationsNCT06070012
Recruiting
Phase 2

Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

Metastatic Uveal MelanomaMetastatic Uveal Melanoma in the Liver
University of Miami30 enrolled1 locationNCT06627244
Recruiting

Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects

Uveal MelanomaChoroidal MelanomaIndeterminate Lesions+1 more
Aura Biosciences15 enrolled1 locationNCT07421739
Recruiting
Phase 3

Neoadjuvant Darovasertib in Primary Uveal Melanoma

Uveal Melanoma
IDEAYA Biosciences520 enrolled87 locationsNCT07015190
Recruiting
Phase 1

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma

MelanomaMetastatic MelanomaUveal Melanoma+1 more
Memorial Sloan Kettering Cancer Center30 enrolled2 locationsNCT05607095